Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDA update.

Russell Katz

    Epilepsy Research
    |December 27, 2005
    PubMed
    Summary
    This summary is machine-generated.

    The FDA is updating its approach to antiepileptic drug (AED) development, focusing on pediatric studies and monotherapy evaluations. Recent approvals were for existing drugs, with ongoing review of adverse events and historical control data for new AEDs.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Development and Application of a Liquid Chromatography-Mass Spectrometry Method for Residual Iodixanol Quantification in AAV-Based Gene Therapy Product Development.

    Human gene therapy·2021
    Same author

    A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.

    Movement disorders : official journal of the Movement Disorder Society·2020
    Same author

    Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases.

    Therapeutic innovation & regulatory science·2018
    Same author

    New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.

    Movement disorders : official journal of the Movement Disorder Society·2017
    Same author

    Building a roadmap for developing combination therapies for Alzheimer's disease.

    Expert review of neurotherapeutics·2015
    Same author

    Charting a path toward combination therapy for Alzheimer's disease.

    Expert review of neurotherapeutics·2014

    Area of Science:

    • Neurology
    • Clinical Pharmacology
    • Regulatory Science

    Background:

    • The Food and Drug Administration (FDA) activity in antiepileptic drug (AED) development is evolving.
    • Key areas include pediatric drug development and the evaluation of AEDs as monotherapy.

    Purpose of the Study:

    • To provide an update on FDA activities related to AED development.
    • To review challenges and FDA policies concerning pediatric AED studies.
    • To outline the FDA's approach to evaluating AEDs for monotherapy use.

    Main Methods:

    • Review of FDA approval actions and regulatory guidance since January 2002.
    • Analysis of policies related to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA).
    • Examination of challenges and potential methodologies for antiepileptic drug monotherapy trials, including the use of historical controls.

    Related Experiment Videos

    Main Results:

    • Since 2002, 47 approval actions for 10 AEDs were issued, with no new chemical entities approved.
    • Lyrica (pregabalin) received an approvable letter for specific indications.
    • FDA is actively reviewing post-marketing adverse event reports, including suicidality, and assessing the use of historical controls for monotherapy trials.

    Conclusions:

    • The FDA continues to refine its regulatory framework for AEDs, emphasizing pediatric safety and efficacy.
    • Monotherapy trials for AEDs present significant methodological and ethical challenges.
    • The agency is exploring the use of historical controls to facilitate the development of new AEDs, particularly for monotherapy indications.